| Year |
Citation |
Score |
| 2023 |
Ligibel JA, Zheng Y, Barry WT, Sella T, Ruddy KJ, Greaney ML, Rosenberg SM, Emmons KM, Partridge AH. Effects of an educational physical activity intervention in young women with newly diagnosed breast cancer: Findings from the Young and Strong Study. Cancer. PMID 37016839 DOI: 10.1002/cncr.34779 |
0.319 |
|
| 2022 |
Anderson KS, Erick TK, Chen M, Daley H, Campbell M, Colson Y, Mihm M, Zakka LR, Hopper M, Barry W, Winer EP, Dranoff G, Overmoyer B. The feasibility of using an autologous GM-CSF-secreting breast cancer vaccine to induce immunity in patients with stage II-III and metastatic breast cancers. Breast Cancer Research and Treatment. PMID 35482127 DOI: 10.1007/s10549-022-06562-y |
0.33 |
|
| 2021 |
Parsons HA, Macrae ER, Guo H, Li T, Barry WT, Tayob N, Wulf GM, Isakoff SJ, Krop IE. Phase II Single-Arm Study to Assess Trastuzumab and Vinorelbine in Advanced Breast Cancer Patients With HER2-Negative Tumors and HER2-Positive Circulating Tumor Cells. Jco Precision Oncology. 5: 896-903. PMID 34994617 DOI: 10.1200/PO.20.00461 |
0.352 |
|
| 2021 |
Tolaney SM, Tayob N, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Hu J, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, ... ... Barry W, et al. Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2003398. PMID 34077270 DOI: 10.1200/JCO.20.03398 |
0.37 |
|
| 2021 |
Ligibel JA, Huebner L, Rugo HS, Burstein HJ, Toppmeyer DL, Anders CK, Ma C, Barry WT, Suman V, Carey LA, Partridge AH, Hudis CA, Winer EP. Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance). Jnci Cancer Spectrum. 5: pkab025. PMID 33981951 DOI: 10.1093/jncics/pkab025 |
0.351 |
|
| 2021 |
Tolaney SM, Ziehr DR, Guo H, Ng MR, Barry WT, Higgins MJ, Isakoff SJ, Brock JE, Ivanova EV, Paweletz CP, Demeo MK, Ramaiya NH, Overmoyer BA, Jain RK, Winer EP, et al. Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients. The Oncologist. PMID 33978307 DOI: 10.1002/onco.13809 |
0.354 |
|
| 2020 |
Garrido-Castro AC, Spurr LF, Hughes ME, Li YY, Cherniack AD, Kumari P, Lloyd MR, Bychkovsky B, Barroso-Sousa R, Di Lascio S, Jain E, Files JL, Mohammed-Abreu A, Krevalin M, MacKichan C, ... Barry WT, et al. Genomic characterization of de novo metastatic breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33293374 DOI: 10.1158/1078-0432.CCR-20-1720 |
0.383 |
|
| 2020 |
Lee EK, Xiong N, Cheng SC, Barry WT, Penson RT, Konstantinopoulos PA, Hoffman MA, Horowitz N, Dizon DS, Stover EH, Wright AA, Campos SM, Krasner C, Morrissey S, Whalen C, et al. Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial. Gynecologic Oncology. PMID 32771276 DOI: 10.1016/J.Ygyno.2020.07.028 |
0.365 |
|
| 2020 |
Magbanua MJM, Hendrix LH, Hyslop T, Barry WT, Winer EP, Hudis C, Toppmeyer D, Carey LA, Partridge AH, Pierga JY, Fehm T, Vidal-Martínez J, Mavroudis D, Garcia-Saenz JA, Stebbing J, et al. Serial analysis of circulating tumor cells in metastatic breast cancer receiving first-line chemotherapy. Journal of the National Cancer Institute. PMID 32770247 DOI: 10.1093/Jnci/Djaa113 |
0.361 |
|
| 2020 |
Sella T, Dowton AA, Meyer ME, Ruddy KJ, Yeh ED, Barry WT, Partridge AH. The utility of magnetic resonance imaging in early-stage breast cancer survivors-An institutional experience and literature review. The Breast Journal. PMID 32754998 DOI: 10.1111/Tbj.13997 |
0.457 |
|
| 2020 |
Metzger O, Leone JP, Li T, Tan-Wasielewski Z, Trippa L, Barry WT, Younger J, Lawler E, Walker L, Freedman RA, Tolaney SM, Krop I, Winer EP, Lin NU. Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 32461105 DOI: 10.1016/J.Annonc.2020.05.014 |
0.448 |
|
| 2020 |
Lietz CE, Garbutt C, Barry WT, Deshpande V, Chen YL, Lozano-Calderon SA, Wang Y, Lawney B, Ebb D, Cote GM, Duan Z, Hornicek FJ, Choy E, Petur Nielsen G, Haibe-Kains B, et al. MicroRNA-mRNA networks define translatable molecular outcome phenotypes in osteosarcoma. Scientific Reports. 10: 4409. PMID 32157112 DOI: 10.1038/S41598-020-61236-3 |
0.315 |
|
| 2020 |
Isakoff SJ, Adams S, Soliman HH, Tung N, Barry WT, Hu J, Trippa L, Deering R, Parker J, Park H, Brachtel EF, Ellisen LW, Severgnini M, Peterkin D, Tolaney SM. Abstract P3-09-15: A phase 1b study of PVX-410 (PVX) vaccine plus durvalumab (DUR) as adjuvant therapy in HLA-A2+ early stage triple negative breast cancer (eTNBC) to assess safety and immune response Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P3-09-15 |
0.352 |
|
| 2020 |
Ruddy KJ, Trippa L, Hu J, Barry WT, Dang CT, Yardley DA, Isakoff SJ, Valero VV, Faggen MG, Mulvey TM, Bose R, Weckstein DJ, Wolff AC, Reeder-Hayes KE, Rugo HS, et al. Abstract P2-13-02: Chemotherapy-related amenorrhea (CRA) after adjuvant trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT trial) Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P2-13-02 |
0.413 |
|
| 2019 |
Sharma MR, Mehrotra S, Gray E, Wu K, Barry WT, Hudis C, Winer EP, Lyss AP, Toppmeyer DL, Moreno-Aspitia A, Lad TE, Velasco M, Overmoyer B, Rugo HS, Ratain MJ, et al. Personalized Management of Chemotherapy-Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance). Journal of Clinical Pharmacology. PMID 31802506 DOI: 10.1002/Jcph.1559 |
0.349 |
|
| 2019 |
Song Y, Barry WT, Seah DS, Tung NM, Garber JE, Lin NU. Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers. Cancer. PMID 31581314 DOI: 10.1002/Cncr.32540 |
0.442 |
|
| 2019 |
Leone JP, Duda DG, Hu J, Barry WT, Trippa L, Gerstner ER, Jain RK, Tan S, Lawler E, Winer EP, Lin NU, Tolaney SM. A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases. Breast Cancer Research and Treatment. PMID 31541381 DOI: 10.1007/S10549-019-05445-Z |
0.445 |
|
| 2019 |
Mayer EL, DeMichele A, Rugo HS, Miller K, Waks AG, Come SE, Mulvey T, Jeselsohn R, Overmoyer B, Guo H, Barry WT, Bartlett CH, Koehler M, Winer EP, Burstein HJ. A Phase II Feasibility Study of Palbociclib in Combination with Adjuvant Endocrine Therapy for Hormone Receptor Positive Invasive Breast Carcinoma. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 31250880 DOI: 10.1093/Annonc/Mdz198 |
0.459 |
|
| 2019 |
Goel S, Pernas S, Tan-Wasielewski Z, Barry WT, Bardia A, Rees R, Andrews C, Tahara RK, Trippa L, Mayer EL, Winer EP, Spring LM, Tolaney SM. Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial. Clinical Breast Cancer. PMID 31235441 DOI: 10.1016/J.Clbc.2019.05.010 |
0.458 |
|
| 2019 |
Laws A, Hughes ME, Hu J, Barry WT, Dominici L, Nakhlis F, Barbie T, Duggan M, Weiss A, Rhei E, Carter K, Nimbkar S, Schnitt SJ, King TA. Impact of Residual Nodal Disease Burden on Technical Outcomes of Sentinel Lymph Node Biopsy for Node-Positive (cN1) Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Annals of Surgical Oncology. PMID 31222687 DOI: 10.1245/S10434-019-07515-4 |
0.392 |
|
| 2019 |
Waks AG, Stover DG, Guerriero JL, Dillon DA, Barry WT, Gjini E, Hartl CA, Lo WT, Savoie J, Brock J, Wesolowski R, Li Z, Damicis A, Philips AV, Wu Y, et al. The immune microenvironment in hormone receptor-positive breast cancer before and after preoperative chemotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31061067 DOI: 10.1158/1078-0432.Ccr-19-0173 |
0.459 |
|
| 2019 |
Bellon JR, Guo H, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Hudis CA, et al. Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). Breast Cancer Research and Treatment. PMID 31004299 DOI: 10.1007/S10549-019-05238-4 |
0.458 |
|
| 2019 |
Tolaney SM, Guo H, Pernas S, Barry WT, Dillon DA, Ritterhouse L, Schneider BP, Shen F, Fuhrman K, Baltay M, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, et al. Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1900066. PMID 30939096 DOI: 10.1200/Jco.19.00066 |
0.452 |
|
| 2019 |
Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Cadoo KA, Shapiro GI, Mayer EL, O'Cearbhaill RE, Coleman RL, Kochupurakkal B, Whalen C, Curtis J, Farooq S, Luo W, Eismann J, et al. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. The Lancet. Oncology. PMID 30880072 DOI: 10.1016/S1470-2045(18)30905-7 |
0.391 |
|
| 2019 |
Barroso-Sousa R, Barry WT, Guo H, Dillon D, Tan YB, Fuhrman K, Osmani W, Getz A, Baltay M, Dang C, Yardley D, Moy B, Marcom PK, Mittendorf EA, Krop IE, et al. The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 30753274 DOI: 10.1093/Annonc/Mdz047 |
0.426 |
|
| 2019 |
Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel BJ, Buss MK, Nattam SR, Hurteau J, Luo W, Curtis J, Whalen C, Kohn EC, Ivy SP, et al. Overall survival and updated progression-free survival outcomes in a randomized phase 2 study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 30753272 DOI: 10.1093/Annonc/Mdz018 |
0.363 |
|
| 2019 |
Partridge AH, Ruddy KJ, Barry WT, Greaney ML, Ligibel JA, Sprunck-Harrild KM, Rosenberg SM, Baker EL, Hoverman JR, Emmons KM. A randomized study to improve care for young women with breast cancer at community and academic medical oncology practices in the United States: The Young and Strong study. Cancer. PMID 30707756 DOI: 10.1002/Cncr.31984 |
0.388 |
|
| 2019 |
Mayer EL, Abramson VG, Jankowitz RC, Falkson CI, Marcom PK, Traina TA, Carey LA, Rimawi MF, Specht JM, Miller K, Stearns V, Perou CM, Richardson AL, Tung NM, Barry WT, et al. TBCRC 030: A randomized phase II study of preoperative cisplatin versus paclitaxel in TNBC—Evaluating the homologous recombination deficiency (HRD) biomarker. Journal of Clinical Oncology. 37: 507-507. DOI: 10.1200/Jco.2019.37.15_Suppl.507 |
0.327 |
|
| 2019 |
Jeselsohn R, Guo H, Rees R, Barry W, Barlett C, Tung N, Krop I, Brown M, Winer E. Abstract PD1-05: Results from the phase Ib/II clinical trial of bazedoxifene and palbociclib in hormone receptor positive metastatic breast cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Pd1-05 |
0.475 |
|
| 2018 |
Metzger-Filho O, Ferreira AR, Jeselsohn R, Barry WT, Dillon DA, Brock JE, Vaz-Luis I, Hughes ME, Winer EP, Lin NU. Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade. The Oncologist. PMID 30518616 DOI: 10.1634/Theoncologist.2018-0363 |
0.337 |
|
| 2018 |
Choi J, Laws A, Hu J, Barry W, Golshan M, King T. Correction to: Margins in Breast-Conserving Surgery After Neoadjuvant Therapy. Annals of Surgical Oncology. PMID 30145646 DOI: 10.1245/S10434-018-6721-1 |
0.33 |
|
| 2018 |
Laws A, Anderson K, Hu J, McLean K, Novak L, Dominici LS, Nakhlis F, Carty M, Caterson S, Chun Y, Duggan M, Barry W, Connell N, Golshan M, King TA. Implementation of a Venous Thromboembolism Prophylaxis Protocol Using the Caprini Risk Assessment Model in Patients Undergoing Mastectomy. Annals of Surgical Oncology. PMID 30128903 DOI: 10.1245/S10434-018-6696-Y |
0.332 |
|
| 2018 |
Choi J, Laws A, Hu J, Barry W, Golshan M, King T. Margins in Breast-Conserving Surgery After Neoadjuvant Therapy. Annals of Surgical Oncology. PMID 30128902 DOI: 10.1245/S10434-018-6702-4 |
0.406 |
|
| 2018 |
Grossmith S, Nguyen A, Hu J, Plichta JK, Nakhlis F, Cutone L, Dominici L, Golshan M, Duggan M, Carter K, Rhei E, Barbie T, Calvillo K, Nimbkar S, Bellon J, ... ... Barry W, et al. Multidisciplinary Management of the Axilla in Patients with cT1-T2 N0 Breast Cancer Undergoing Primary Mastectomy: Results from a Prospective Single-Institution Series. Annals of Surgical Oncology. PMID 29868979 DOI: 10.1245/S10434-018-6525-3 |
0.411 |
|
| 2018 |
Moossdorff M, Nakhlis F, Hu J, Barry WT, Losk K, Haskett C, Smidt ML, King TA. The Potential Impact of AMAROS on the Management of the Axilla in Patients with Clinical T1-2N0 Breast Cancer Undergoing Primary Total Mastectomy. Annals of Surgical Oncology. PMID 29855827 DOI: 10.1245/S10434-018-6519-1 |
0.41 |
|
| 2018 |
Li D, McCall LM, Hahn OM, Hudis CA, Cohen HJ, Muss HB, Jatoi A, Lafky JM, Ballman KV, Winer EP, Tripathy D, Schneider B, Barry W, Dickler MN, Hurria A. Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study. Breast Cancer Research and Treatment. PMID 29789969 DOI: 10.1007/s10549-018-4828-5 |
0.367 |
|
| 2018 |
Criscitiello C, Golshan M, Barry WT, Viale G, Wong S, Santangelo M, Curigliano G. Impact of neoadjuvant chemotherapy and pathological complete response on eligibility for breast-conserving surgery in patients with early breast cancer: A meta-analysis. European Journal of Cancer (Oxford, England : 1990). 97: 1-6. PMID 29734046 DOI: 10.1016/J.Ejca.2018.03.023 |
0.486 |
|
| 2018 |
Freedman RA, Keating NL, Lin NU, Winer EP, Vaz-Luis I, Lii J, Exman P, Barry WT. Breast cancer-specific survival by age: Worse outcomes for the oldest patients. Cancer. PMID 29499074 DOI: 10.1002/Cncr.31308 |
0.47 |
|
| 2018 |
Poorvu PD, Vaz-Luis I, Freedman RA, Lin NU, Barry WT, Winer EP, Hassett MJ. Variation in guideline-concordant care for elderly patients with metastatic breast cancer in the United States. Breast Cancer Research and Treatment. PMID 29332137 DOI: 10.1007/S10549-018-4659-4 |
0.457 |
|
| 2018 |
Magbanua MJM, Rugo HS, Wolfe DM, Hauranieh L, Roy R, Pendyala P, Sosa E, Scott JH, Lee JS, Pitcher BN, Hyslop TM, Barry WT, Isakoff SJ, Dickler MN, Van't Veer LJ, et al. Expanded genomic profiling of circulating tumor cells in metastatic breast cancer patients to assess biomarker status and biology over time. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29311117 DOI: 10.1158/1078-0432.Ccr-17-2312 |
0.448 |
|
| 2018 |
Stover DG, Parsons HA, Ha G, Freeman SS, Barry WT, Guo H, Choudhury AD, Gydush G, Reed SC, Rhoades J, Rotem D, Hughes ME, Dillon DA, Partridge AH, Wagle N, et al. Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017760033. PMID 29298117 DOI: 10.1200/Jco.2017.76.0033 |
0.317 |
|
| 2018 |
Ligibel JA, Barry WT, Alfano CM, Hershman DL, Irwin ML, Neuhouser M, Thomson CA, Delahanty L, Frank E, Spears P, Paskett ED, Hopkins JO, Bernstein V, Stearns V, White JR, et al. The Breast Cancer Weight Loss (BWEL) trial: Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early-stage breast cancer (Alliance A011401). Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.15_Suppl.Tps598 |
0.447 |
|
| 2018 |
Barroso-Sousa R, Guo H, Barry WT, Winship G, Overmoyer B, Duda DG, Tolaney SM. A phase II study of nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer (mTNBC). Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.15_Suppl.Tps1119 |
0.444 |
|
| 2018 |
Garrido-Castro AC, Barry WT, Traina TA, Wesolowski R, Tung NM, Keenan T, Allen EMV, Lin NU, Winer EP, Krop IE, Tolaney SM. A randomized phase II trial of carboplatin with or without nivolumab in first- or second-line metastatic TNBC. Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.15_Suppl.Tps1118 |
0.4 |
|
| 2018 |
Barroso-Sousa R, Barry WT, Kumthekar P, Guo H, Silvestri KM, Krop IE, Winer EP, Tolaney SM, Lin NU. A phase II study of atezolizumab (Atezo) combined with pertuzumab (P) and high-dose trastuzumab (H) for the treatment of central nervous system (CNS) metastases in patients with Her2-positive (HER2+) metastatic breast cancer (MBC). Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.15_Suppl.Tps1100 |
0.368 |
|
| 2018 |
Laws A, Hughes ME, Hu J, Barry WT, Dominici LS, Nakhlis F, Barbie T, Duggan MM, Weiss A, Rhei E, Carter K, Calvillo K, Nimbkar S, Schnitt SJ, King TA. Impact of residual nodal disease burden on sentinel node mapping and accuracy of intraoperative frozen section in node positive (cN1) breast cancer patients treated with neoadjuvant chemotherapy (NAC). Journal of Clinical Oncology. 36: 584-584. DOI: 10.1200/Jco.2018.36.15_Suppl.584 |
0.334 |
|
| 2018 |
Liu JF, Barry WT, Wenham RM, Hendrickson AEW, Armstrong DK, Chan N, Cohn DE, Lee J, Penson RT, Cristea MC, Abbruzzese JL, Matsuo K, Olawaiye A, Farooq S, Swisher EM, et al. A phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca). Journal of Clinical Oncology. 36: 5519-5519. DOI: 10.1200/Jco.2018.36.15_Suppl.5519 |
0.376 |
|
| 2018 |
Barroso-Sousa R, Guo H, Barry WT, Ferreira AR, Rees R, Winer EP, Wagle N, Tolaney SM. A phase I study of palbociclib (PALBO) plus everolimus (EVE) and exemestane (EXE) in hormone-receptor positive (HR+)/HER2- metastatic breast cancer (MBC) after progression on a CDK4/6 inhibitor (CDK4/6i): safety, tolerability and pharmacokinetic (PK) analysis. Journal of Clinical Oncology. 36: 1068-1068. DOI: 10.1200/Jco.2018.36.15_Suppl.1068 |
0.377 |
|
| 2018 |
Leone JP, Hu J, Barry WT, Duda DG, Gerstner ER, Jain RK, Tan S, Lawler ES, Winer EP, Lin NU, Tolaney SM. A phase II study of cabozantinib (cabo) alone or in combination with trastuzumab (T) in patients (pts) with breast cancer brain metastases (BCBM). Journal of Clinical Oncology. 36: 1026-1026. DOI: 10.1200/Jco.2018.36.15_Suppl.1026 |
0.365 |
|
| 2018 |
Magbanua M, Hendrix L, Hyslop T, Barry W, Winer E, Hudis C, Toppmeyer D, Burnstein H, Qadir M, Ma C, Scott J, Park J, Rugo H. Abstract P2-01-01: Trajectory patterns of circulating tumor cells (CTC) in chemotherapy-treated metastatic breast cancer (MBC) patients predict poor clinical outcomes: CALGB 40502 (Alliance)/NCCTG N063H study Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P2-01-01 |
0.46 |
|
| 2018 |
Ligibel J, Huebner L, Rugo H, Burstein H, Toppmeyer D, Anders C, Ma C, Hudis C, Winer E, Barry W. Abstract P1-07-04: Physical activity, weight and outcomes in patients receiving first-line chemotherapy for metastatic breast cancer: Results from CALGB 40502 (Alliance) Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P1-07-04 |
0.487 |
|
| 2018 |
Barroso-Sousa R, Gao H, Barry W, Krop I, Schoenfeld J, Tolaney S. Abstract OT1-02-02: A phase II study of pembrolizumab in combination with palliative radiotherapy for metastatic hormone receptor positive breast cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-Ot1-02-02 |
0.474 |
|
| 2018 |
Rugo H, Barry W, Moreno-Aspitia A, Lyss A, Huebner L, Mayer E, Naughton M, Layman R, Carey L, Somer R, Toppmeyer D, Velasco M, Perez E, Hudis C, Winer E. Abstract GS3-06: Long-term follow-up of CALGB 40502/NCCTG N063H (Alliance): A randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-Paclitaxel (NP) or ixabepilone (Ix) +/- bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer (MBC) Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-Gs3-06 |
0.365 |
|
| 2018 |
Waks AG, Stover DG, Barry WT, Dillon DA, Gjini E, Rodig SJ, Brock JE, Baltay M, Savoie J, Winer EP, Krop IE, Tolaney SM. Abstract 4564: The immune microenvironment in hormone receptor-positive breast cancer and treatment outcome following preoperative chemotherapy plus bevacizumab Cancer Research. 78: 4564-4564. DOI: 10.1158/1538-7445.Am2018-4564 |
0.447 |
|
| 2017 |
Sagara Y, Freedman RA, Wong SM, Aydogan F, Nguyen A, Barry WT, Golshan M. Trends in adjuvant therapies after breast-conserving surgery for hormone receptor-positive ductal carcinoma in situ: findings from the National Cancer Database, 2004-2013. Breast Cancer Research and Treatment. PMID 28776282 DOI: 10.1007/S10549-017-4436-9 |
0.4 |
|
| 2017 |
Regan MM, Barry WT. Trial designs and results supporting treatment de-escalation and escalation. Breast (Edinburgh, Scotland). PMID 28673539 DOI: 10.1016/J.Breast.2017.06.020 |
0.302 |
|
| 2017 |
Mehrotra S, Sharma MR, Gray E, Wu K, Barry WT, Hudis C, Winer EP, Lyss AP, Toppmeyer DL, Moreno-Aspitia A, Lad TE, Valasco M, Overmoyer B, Rugo H, Ratain MJ, et al. Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance). The Aaps Journal. PMID 28620884 DOI: 10.1208/S12248-017-0101-9 |
0.422 |
|
| 2017 |
Wong SM, King T, Boileau JF, Barry WT, Golshan M. Population-Based Analysis of Breast Cancer Incidence and Survival Outcomes in Women Diagnosed with Lobular Carcinoma In Situ. Annals of Surgical Oncology. PMID 28455673 DOI: 10.1245/S10434-017-5867-6 |
0.45 |
|
| 2017 |
Di Meglio A, Lin NU, Freedman RA, Barry WT, Winer EP, Vaz-Luis I. Patterns of Utilization of Imaging Studies and Serum Tumor Markers Among Patients With De Novo Metastatic Breast Cancer. Journal of the National Comprehensive Cancer Network : Jnccn. 15: 316-324. PMID 28275032 DOI: 10.6004/Jnccn.2017.0031 |
0.352 |
|
| 2017 |
Vaz-Luis I, Lin NU, Keating NL, Barry WT, Winer EP, Freedman RA. Factors Associated with Early Mortality Among Patients with De Novo Metastatic Breast Cancer: A Population-Based Study. The Oncologist. PMID 28242790 DOI: 10.1634/Theoncologist.2016-0369 |
0.459 |
|
| 2017 |
Ventz S, Barry WT, Parmigiani G, Trippa L. Bayesian response-adaptive designs for basket trials. Biometrics. PMID 28211944 DOI: 10.1111/Biom.12668 |
0.315 |
|
| 2017 |
Wong SM, Freedman RA, Sagara Y, Aydogan F, Barry WT, Golshan M. Growing Use of Contralateral Prophylactic Mastectomy Despite no Improvement in Long-term Survival for Invasive Breast Cancer. Annals of Surgery. 265: 581-589. PMID 28169929 DOI: 10.1097/Sla.0000000000001698 |
0.46 |
|
| 2017 |
Chen WY, Winer EP, Barry WT, Hudis CA, Openshaw TH, Visvanathan K, Symington B, Matyka C, Holmes MD. ABC trial (A011502): A randomized phase III double blinded placebo controlled trial of aspirin as adjuvant therapy for node positive breast cancer. Journal of Clinical Oncology. 35: TPS586-TPS586. DOI: 10.1200/Jco.2017.35.15_Suppl.Tps586 |
0.47 |
|
| 2017 |
Konstantinopoulos PA, Liu JF, Barry WT, Krasner CN, Buss MK, Birrer MJ, Farooq S, Campos SM, Stover E, Schumer S, Wright AA, Curtis J, Peralta A, Whalen C, Dizon DS, et al. Phase 2, two-group, two-stage, open-label study of avelumab in patients with microsatellite stable, microsatellite instable and POLE-mutated recurrent or persistent endometrial cancer. Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.Tps5615 |
0.348 |
|
| 2017 |
Isakoff SJ, Tolaney SM, Tung NM, Adams S, Soliman HH, Brachtel EF, Habin KR, Bauer LJ, Ellisen LW, Severgnini M, Barry WT, Peterkin D. A phase 1b study of safety and immune response to PVX-410 vaccine alone and in combination with durvalumab (MEDI4736) in HLA-A2+ patients following adjuvant therapy for stage 2/3 triple negative breast cancer. Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.Tps1126 |
0.4 |
|
| 2017 |
Isakoff SJ, Rogers GS, Hill S, McMullan P, Habin KR, Park H, Bartenstein DW, Chen ST, Barry WT, Overmoyer B. An open label, phase II trial of continuous low-irradiance photodynamic therapy (CLIPT) using verteporfin for the treatment of cutaneous breast cancer metastases. Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.Tps1121 |
0.423 |
|
| 2017 |
Waks AG, Barry WT, Gjini E, Dillon D, Rodig S, Brock JE, Baltay M, Savoie J, Stover DG, Winer EP, Krop IE, Tolaney SM. Immune biomarkers and treatment (tx) outcome in hormone receptor-positive (HR+) breast cancer (BC) patients (pts) treated with preoperative chemotherapy (preop chemo) plus bevacizumab (bev). Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.E12134 |
0.391 |
|
| 2017 |
Liu JF, Barry WT, Birrer MJ, Lee J, Buckanovich RJ, Fleming GF, Rimel B, Buss MK, Nattam SR, Hurteau J, Luo W, Farooq S, Whalen C, Kohn EC, Ivy SP, et al. Overall survival and updated progression-free survival results from a randomized phase 2 trial comparing the combination of olaparib and cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer. Journal of Clinical Oncology. 35: 5535-5535. DOI: 10.1200/Jco.2017.35.15_Suppl.5535 |
0.391 |
|
| 2017 |
Tolaney SM, Barry WT, Guo H, Dillon D, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Overmoyer B, et al. Seven-year (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC). Journal of Clinical Oncology. 35: 511-511. DOI: 10.1200/Jco.2017.35.15_Suppl.511 |
0.444 |
|
| 2017 |
Stover DG, Parsons HA, Ha G, Freeman S, Barry WT, Guo H, Gydush G, Reed S, Rhoades J, Rotem D, Hughes ME, Krop IE, Tolaney SM, Wagle N, Getz G, et al. Genome-wide copy number analysis of cell-free DNA from patients with chemotherapy-resistant metastatic triple-negative breast cancer. Journal of Clinical Oncology. 35: 1092-1092. DOI: 10.1200/Jco.2017.35.15_Suppl.1092 |
0.445 |
|
| 2017 |
Luis IMVD, Guo H, Barry WT, Krop IE, Wagle N, Lowe A, Gore D, Andrews C, Osmani W, Isakoff SJ, Tung NM, Winer EP, Lin NU, Freedman RA. A phase II study of eribulin mesylate in combination with trastuzumab and pertuzumab in patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC). Journal of Clinical Oncology. 35: 1034-1034. DOI: 10.1200/Jco.2017.35.15_Suppl.1034 |
0.416 |
|
| 2017 |
Filho OM, Goel S, Barry WT, Hamilton EP, Tolaney SM, Yardley DA, Rees R, Demeo M, Mills C, Hafner M, Winer EP, Zhao J, Krop IE. A mouse-human phase I co-clinical trial of taselisib in combination with TDM1 in advanced HER2-positive breast cancer (MBC). Journal of Clinical Oncology. 35: 1030-1030. DOI: 10.1200/Jco.2017.35.15_Suppl.1030 |
0.37 |
|
| 2017 |
Martin M, Loibl S, Hyslop T, de la Haba-Rodriguez J, Aktas B, Cirrincione C, Carrasco EM, Mehta K, Barry WT, Morales S, Carey LA, Garcia Saenz JA, Partridge A, Martinez N, Hahn OM, et al. Evaluating the addition of bevacizumab (Bev) to endocrine therapy as first-line treatment for hormone-receptor positive (HR+)/HER2-negative advanced breast cancer (ABC): Pooled-analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials. Journal of Clinical Oncology. 35: 1012-1012. DOI: 10.1200/Jco.2017.35.15_Suppl.1012 |
0.345 |
|
| 2017 |
Wang ZC, Birkbak NJ, Barry WT, Roberts TM, Winer EP, Iglehart JD, Matulonis UA, Ivy SP, Liu JF. Abstract NTOC-112: GENOMIC SCARS AND CLINICAL RESPONSE TO COMBINATION THERAPY OF PARP AND ANGIOGENESIS INHIBITORS IN OVARIAN CANCER Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Ovcasymp16-Ntoc-112 |
0.396 |
|
| 2017 |
Stover D, Selfors L, Winer E, Partridge A, Barry W. Abstract P1-07-05: Integrated transcriptional analysis of the triple negative 'proliferation paradox': High proliferation, chemosensitivity, and poor prognosis Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P1-07-05 |
0.448 |
|
| 2017 |
Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Farooq S, Cadoo K, Whalen C, Luo W, Liu H, Aghajanian C, Solit DB, Mills GB, Taylor BS, Won H, Berger MF, et al. Abstract CT008: Phase I study of the alpha specific PI3-Kinase inhibitor BYL719 and the poly (ADP-Ribose) polymerase (PARP) inhibitor olaparib in recurrent ovarian and breast cancer: Analysis of the dose escalation and ovarian cancer expansion cohort Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Ct008 |
0.44 |
|
| 2017 |
Kuang Y, Siddiqui B, Hu J, Barry WT, Lin NU, Wagle N, Kirschmeier P, Jänne PA, Paweletz C, Krop I, Winer EP, Brown M, Jeselsohn R. Abstract 4950: The emergence of ESR1 mutations is associated with aromatase inhibitor and fulvestrant therapy Cancer Research. 77: 4950-4950. DOI: 10.1158/1538-7445.Am2017-4950 |
0.338 |
|
| 2017 |
Criscitiello C, Golshan M, Barry WT, Viale G, Wong S, Santangelo M, Curigliano G. 170PImpact of neoadjuvant therapy (NT) and pathological complete response (pCR) on breast-conserving surgery (BCS) in patients (pts) with breast cancer (BC): A meta-analysis Annals of Oncology. 28. DOI: 10.1093/Annonc/Mdx362.020 |
0.466 |
|
| 2017 |
Bellon JR, Tolaney S, Guo H, Barry WT, Burstein HJ, Winer E, Harris JR. Local-Regional Recurrence in Women with N0/N1mi, HER2-Positive Breast Cancer: Results from a Prospective Multi-institutional Study (The APT Trial) International Journal of Radiation Oncology Biology Physics. 99. DOI: 10.1016/J.Ijrobp.2017.06.141 |
0.432 |
|
| 2016 |
Liu MC, Pitcher BN, Mardis ER, Davies SR, Friedman PN, Snider JE, Vickery TL, Reed JP, DeSchryver K, Singh B, Gradishar WJ, Perez EA, Martino S, Citron ML, Norton L, ... ... Barry WT, et al. PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance). Npj Breast Cancer. 2. PMID 28691057 DOI: 10.1038/npjbcancer.2015.23 |
0.36 |
|
| 2016 |
Barry WT, Ruddy KJ, Greaney M, Rosenberg SM, Sprunck-Harrild K, Morgan E, Walsh S, Emmons K, Partridge AH. Impact of Young and Strong on physical activity in young breast cancer survivors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 34: 175. PMID 28151369 DOI: 10.1200/Jco.2016.34.3_Suppl.175 |
0.433 |
|
| 2016 |
Matulonis UA, Wulf GM, Barry WT, Birrer M, Westin SN, Farooq S, Bell-McGuinn KM, Obermayer E, Whalen C, Spagnoletti T, Luo W, Liu H, Hok RC, Aghajanian C, Solit DB, et al. Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high grade serous ovarian and breast cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 27993796 DOI: 10.1093/Annonc/Mdw672 |
0.366 |
|
| 2016 |
Kelley MJ, Jha G, Shoemaker D, Herndon JE, Gu L, Barry WT, Crawford J, Ready N. Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. Cancer Investigation. 1-4. PMID 27911119 DOI: 10.1080/07357907.2016.1253710 |
0.355 |
|
| 2016 |
Tolaney SM, Ziehr DR, Guo H, Ng MR, Barry WT, Higgins MJ, Isakoff SJ, Brock JE, Ivanova EV, Paweletz CP, Demeo MK, Ramaiya NH, Overmoyer BA, Jain RK, Winer EP, et al. Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients. The Oncologist. PMID 27789775 DOI: 10.1634/Theoncologist.2016-0229 |
0.425 |
|
| 2016 |
Vaz-Luis I, Lin NU, Keating NL, Barry WT, Lii J, Burstein HJ, Winer EP, Freedman RA. Treatment of early-stage human epidermal growth factor 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab. Breast Cancer Research and Treatment. PMID 27484879 DOI: 10.1007/S10549-016-3927-4 |
0.419 |
|
| 2016 |
Stover DG, Coloff JL, Barry WT, Brugge JS, Winer EP, Selfors LM. The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression-Based Meta-Analysis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27330058 DOI: 10.1158/1078-0432.Ccr-16-0471 |
0.475 |
|
| 2016 |
Di Meglio A, Freedman RA, Lin NU, Barry WT, Metzger-Filho O, Keating NL, King TA, Sertoli MR, Boccardo F, Winer EP, Vaz-Luis I. Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis. Breast Cancer Research and Treatment. PMID 27271765 DOI: 10.1007/S10549-016-3845-5 |
0.443 |
|
| 2016 |
Jeselsohn R, Barry WT, Migliaccio I, Biagioni C, Zhao J, de Tribolet-Hardy J, Guarducci C, Bonechi M, Laing N, Winer EP, Brown M, Di Leo A, Malorni L. TransCONFIRM: Identification of a genetic signature of response to fulvestrant in advanced hormone receptor positive breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27185372 DOI: 10.1158/1078-0432.Ccr-16-0148 |
0.445 |
|
| 2016 |
Dickler MN, Barry WT, Cirrincione CT, Ellis MJ, Moynahan ME, Innocenti F, Hurria A, Rugo HS, Lake DE, Hahn O, Schneider BP, Tripathy D, Carey LA, Winer EP, Hudis CA. Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27138575 DOI: 10.1200/Jco.2015.66.1595 |
0.442 |
|
| 2016 |
Truong SR, Barry WT, Moslehi JJ, Baker EL, Mayer EL, Partridge AH. Evaluating the Utility of Baseline Cardiac Function Screening in Early-Stage Breast Cancer Treatment. The Oncologist. PMID 27107002 DOI: 10.1634/Theoncologist.2015-0449 |
0.419 |
|
| 2016 |
Wong SM, Freedman RA, Sagara Y, Aydogan F, Barry WT, Golshan M. Growing Use of Contralateral Prophylactic Mastectomy Despite no Improvement in Long-term Survival for Invasive Breast Cancer. Annals of Surgery. PMID 26967636 DOI: 10.1097/SLA.0000000000001698 |
0.307 |
|
| 2016 |
Telli ML, Timms KM, Reid JE, Hennessy B, Mills GB, Jensen KC, Szallasi Z, Barry WT, Winer EP, Tung N, Isakoff SJ, Ryan PD, Greene-Colozzi A, Gutin A, Sangale Z, et al. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple Negative Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26957554 DOI: 10.1158/1078-0432.Ccr-15-2477 |
0.425 |
|
| 2016 |
Huh SJ, Oh H, Peterson MA, Almendro V, Hu R, Bowden M, Lis RT, Cotter MB, Loda M, Barry WT, Polyak K, Tamimi RM. The proliferative activity of mammary epithelial cells in normal tissue predicts breast cancer risk in premenopausal women. Cancer Research. PMID 26941287 DOI: 10.1158/0008-5472.Can-15-1927 |
0.437 |
|
| 2016 |
Sagara Y, Freedman RA, Vaz-Luis I, Mallory MA, Wong SM, Aydogan F, DeSantis S, Barry WT, Golshan M. Patient Prognostic Score and Associations With Survival Improvement Offered by Radiotherapy After Breast-Conserving Surgery for Ductal Carcinoma In Situ: A Population-Based Longitudinal Cohort Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 34: 1190-6. PMID 26834064 DOI: 10.1200/Jco.2015.65.1869 |
0.435 |
|
| 2016 |
Shu S, Lin CY, He HH, Witwicki RM, Tabassum DP, Roberts JM, Janiszewska M, Jin Huh S, Liang Y, Ryan J, Doherty E, Mohammed H, Guo H, Stover DG, Ekram MB, ... ... Barry WT, et al. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature. PMID 26735014 DOI: 10.1038/Nature16508 |
0.379 |
|
| 2016 |
Meglio AD, Lin NU, Freedman RA, Barry WT, Winer EP, Luis IV. Patterns of utilization of imaging and tumor markers (TM) among metastatic breast cancer (MBC) patients (pts). Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.E18224 |
0.378 |
|
| 2016 |
Luis IV, Lin NU, Freedman RA, Barry WT, Winer EP, Hassett MJ. Quality of care for metastatic breast cancer (MBC). Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.E18031 |
0.375 |
|
| 2016 |
Luis IV, Lin NU, Keating NL, Barry WT, Lii J, Burstein HJ, Winer EP, Freedman RA. Factors associated with non use of adjuvant trastuzumab in older patients with HER2+ breast cancer. Journal of Clinical Oncology. 34: 601-601. DOI: 10.1200/Jco.2016.34.15_Suppl.601 |
0.439 |
|
| 2016 |
Innocenti F, Owzar K, Jiang C, Sibley A, Mulkey F, Carey LA, Tripathy D, Schneider BP, Barry WT, Winer EP, Hudis CA, McLeod HL, Dickler MN. A genome-wide association study (GWAS) of progression-free survival (PFS) in metastatic breast cancer (MBC) patients treated with letrozole (L) with or without bevacizumab (B) in CALGB 40503. Journal of Clinical Oncology. 34: 538-538. DOI: 10.1200/Jco.2016.34.15_Suppl.538 |
0.361 |
|
| 2016 |
Rosenberg SM, Ruddy KJ, Barry WT, Sprunck K, Ligibel JA, Domchek SM, Partridge AH. Patterns and predictors of BRCA 1/2 testing in young breast cancer survivors. Journal of Clinical Oncology. 34: 1514-1514. DOI: 10.1200/Jco.2016.34.15_Suppl.1514 |
0.373 |
|
| 2016 |
Duda DG, Ziehr DR, Guo H, Ng M, Barry WT, Higgins MJ, Isakoff SJ, Brock JE, Ivanova E, Paweletz C, Demeo M, Ramaiya NH, Overmoyer B, Jain RK, Winer EP, et al. Effect of cabozantinib treatment on circulating immune cell populations in patients with metastatic triple-negative breast cancer (TNBC). Journal of Clinical Oncology. 34: 1093-1093. DOI: 10.1200/Jco.2016.34.15_Suppl.1093 |
0.41 |
|
| 2016 |
Li D, Dickler MN, McCall LM, Hahn OM, Hudis CA, Cohen HJ, Muss HB, Ballman KV, Winer EP, Tripathy D, Schneider BP, Cirrincione CT, Barry WT, Hurria A. Identifying risk factors for toxicity in patients (Pts) with hormone-receptor positive (HR+) advanced breast cancer treated with bevacizumab plus letrozole: A CALGB 40503 (Alliance) correlative study. Journal of Clinical Oncology. 34: 10047-10047. DOI: 10.1200/Jco.2016.34.15_Suppl.10047 |
0.47 |
|
| 2016 |
Sagara Y, Freedman R, Vaz-Luis I, Mallory M, Wong S, Aydogan F, DeSantis S, Barry W, Golshan M. Abstract P3-12-02: Patient prognostic score and survival benefit offered by radiotherapy for ductal carcinoma in situ Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P3-12-02 |
0.439 |
|
| 2016 |
Meglio AD, Freedman R, Lin N, Barry W, Metzger-Filho O, Keating N, Winer E, Vaz-Luis I. Abstract P1-07-08: Time trends in incidence rates and survival for women with de novo metastatic lobular vs. ductal carcinoma, a population-based study Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P1-07-08 |
0.362 |
|
| 2015 |
Tolaney SM, Boucher Y, Duda DG, Martin JD, Seano G, Ancukiewicz M, Barry WT, Goel S, Lahdenrata J, Isakoff SJ, Yeh ED, Jain SR, Golshan M, Brock J, Snuderl M, et al. Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients. Proceedings of the National Academy of Sciences of the United States of America. 112: 14325-14330. PMID 26578779 DOI: 10.1073/Pnas.1518808112 |
0.455 |
|
| 2015 |
Neupane M, Clark AP, Landini S, Birkbak NJ, Eklund AC, Lim E, Culhane AC, Barry WT, Schumacher SE, Beroukhim R, Szallasi Z, Vidal M, Hill DE, Silver DP. MECP2 Is a Frequently Amplified Oncogene with a Novel Epigenetic Mechanism that Mimics the Role of Activated RAS in Malignancy. Cancer Discovery. PMID 26546296 DOI: 10.1158/2159-8290.Cd-15-0341 |
0.31 |
|
| 2015 |
Carey LA, Berry DA, Cirrincione CT, Barry WT, Pitcher BN, Harris LN, Ollila DW, Krop IE, Henry NL, Weckstein DJ, Anders CK, Singh B, Hoadley KA, Iglesia M, Cheang MC, et al. Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26527775 DOI: 10.1200/Jco.2015.62.1268 |
0.339 |
|
| 2015 |
Wong SM, Freedman RA, Sagara Y, Stamell EF, Desantis SD, Barry WT, Golshan M. The effect of Paget disease on axillary lymph node metastases and survival in invasive ductal carcinoma. Cancer. 121: 4333-40. PMID 26376021 DOI: 10.1002/Cncr.29687 |
0.34 |
|
| 2015 |
Lin NU, Guo H, Yap JT, Mayer IA, Falkson CI, Hobday TJ, Dees EC, Richardson AL, Nanda R, Rimawi MF, Ryabin N, Najita JS, Barry WT, Arteaga CL, Wolff AC, et al. Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26169615 DOI: 10.1200/Jco.2014.60.0353 |
0.367 |
|
| 2015 |
Tolaney SM, Tan S, Guo H, Barry W, Van Allen E, Wagle N, Brock J, Larrabee K, Paweletz C, Ivanova E, Janne P, Overmoyer B, Wright JJ, Shapiro GI, Winer EP, et al. Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer. Investigational New Drugs. PMID 26123926 DOI: 10.1007/S10637-015-0269-8 |
0.421 |
|
| 2015 |
Ligibel JA, Cirrincione CT, Liu M, Citron M, Ingle JN, Gradishar W, Martino S, Sikov W, Michaelson R, Mardis E, Perou CM, Ellis M, Winer E, Hudis CA, Berry D, ... Barry WT, et al. Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance). Journal of the National Cancer Institute. 107. PMID 26113580 DOI: 10.1093/Jnci/Djv179 |
0.429 |
|
| 2015 |
Horton JK, Blitzblau RC, Yoo S, Geradts J, Chang Z, Baker JA, Georgiade GS, Chen W, Siamakpour-Reihani S, Wang C, Broadwater G, Groth J, Palta M, Dewhirst M, Barry WT, et al. Preoperative Single-Fraction Partial Breast Radiation Therapy: A Novel Phase 1, Dose-Escalation Protocol With Radiation Response Biomarkers. International Journal of Radiation Oncology, Biology, Physics. 92: 846-55. PMID 26104938 DOI: 10.1016/J.Ijrobp.2015.03.007 |
0.404 |
|
| 2015 |
Rugo HS, Barry WT, Moreno-Aspitia A, Lyss AP, Cirrincione C, Leung E, Mayer EL, Naughton M, Toppmeyer D, Carey LA, Perez EA, Hudis C, Winer EP. Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 2361-9. PMID 26056183 DOI: 10.1200/Jco.2014.59.5298 |
0.42 |
|
| 2015 |
Sagara Y, Mallory MA, Wong S, Aydogan F, DeSantis S, Barry WT, Golshan M. Survival Benefit of Breast Surgery for Low-Grade Ductal Carcinoma In Situ: A Population-Based Cohort Study. Jama Surgery. PMID 26039049 DOI: 10.1001/Jamasurg.2015.0876 |
0.417 |
|
| 2015 |
Vaz-Luis I, Lin NU, Keating NL, Barry WT, Lii H, Winer EP, Freedman RA. Racial differences in outcomes for patients with metastatic breast cancer by disease subtype. Breast Cancer Research and Treatment. 151: 697-707. PMID 26022349 DOI: 10.1007/S10549-015-3432-1 |
0.469 |
|
| 2015 |
Ruddy KJ, Guo H, Barry W, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Hudis C, et al. Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial). Breast Cancer Research and Treatment. 151: 589-96. PMID 25981899 DOI: 10.1007/s10549-015-3426-z |
0.361 |
|
| 2015 |
Sagara Y, Barry WT, Mallory MA, Vaz-Luis I, Aydogan F, Brock JE, Winer EP, Golshan M, Metzger-Filho O. Surgical Options and Locoregional Recurrence in Patients Diagnosed with Invasive Lobular Carcinoma of the Breast. Annals of Surgical Oncology. PMID 25893416 DOI: 10.1245/S10434-015-4570-8 |
0.38 |
|
| 2015 |
Greaney ML, Sprunck-Harrild K, Ruddy KJ, Ligibel J, Barry WT, Baker E, Meyer M, Emmons KM, Partridge AH. Study protocol for Young & Strong: a cluster randomized design to increase attention to unique issues faced by young women with newly diagnosed breast cancer. Bmc Public Health. 15: 37. PMID 25636332 DOI: 10.1186/S12889-015-1346-9 |
0.384 |
|
| 2015 |
Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Guo H, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. The New England Journal of Medicine. 372: 134-41. PMID 25564897 DOI: 10.1056/Nejmoa1406281 |
0.502 |
|
| 2015 |
Barry WT, Perou CM, Marcom PK, Carey LA, Ibrahim JG. The use of Bayesian hierarchical models for adaptive randomization in biomarker-driven phase II studies. Journal of Biopharmaceutical Statistics. 25: 66-88. PMID 24836519 DOI: 10.1080/10543406.2014.919933 |
0.323 |
|
| 2015 |
Partridge AH, Ruddy KJ, Barry WT, Greaney M, Ligibel JA, Sprunck-Harrild K, Rosenberg SM, Baker E, Hoverman JR, Emmons K. Young and strong: A randomized study to improve care for young women with breast cancer. Journal of Clinical Oncology. 33: 9588-9588. DOI: 10.1200/Jco.2015.33.15_Suppl.9588 |
0.417 |
|
| 2015 |
Liu J, Lee J, Luo W, Birrer MJ, Whalen C, Houston ND, Obermayer E, Spagnoletti T, Barry WT, Kohn EC, Ivy SP, Matulonis U. A phase 1 study optimizing the dosing of olaparib tablet formulation combined with cediranib in recurrent ovarian cancer. Journal of Clinical Oncology. 33: 5559-5559. DOI: 10.1200/Jco.2015.33.15_Suppl.5559 |
0.317 |
|
| 2015 |
Dickler MN, Barry WT, Cirrincione CT, Ellis MJ, Moynahan ME, Innocenti F, Hurria A, Rugo HS, Lake D, Hahn OM, Schneider BP, Tripathy D, Winer EP, Hudis CA. Phase III trial evaluating the addition of bevacizumab to letrozole as first-line endocrine therapy for treatment of hormone-receptor positive advanced breast cancer: CALGB 40503 (Alliance). Journal of Clinical Oncology. 33: 501-501. DOI: 10.1200/Jco.2015.33.15_Suppl.501 |
0.422 |
|
| 2015 |
Luis IMVD, Lin NU, Keating NL, Lii J, Barry WT, Winer EP, Freedman RA. Factors associated with early mortality in metastatic breast cancer (MBC) in a population based cohort. Journal of Clinical Oncology. 33: 1577-1577. DOI: 10.1200/Jco.2015.33.15_Suppl.1577 |
0.385 |
|
| 2015 |
Tolaney SM, Ziehr DR, Guo H, Barry WT, Higgins MJ, Isakoff SJ, Brock JE, Ivanova E, Paweletz C, Demeo M, Ramaiya NH, Overmoyer B, Jain RK, Duda DG, Winer EP. A Phase II study of cabozantinib for metastatic triple-negative breast cancer (TNBC). Journal of Clinical Oncology. 33: 1080-1080. DOI: 10.1200/Jco.2015.33.15_Suppl.1080 |
0.445 |
|
| 2015 |
Sharma M, Gray E, Mehrotra S, Wu K, Barry WT, Hudis CA, Winer EP, Lyss AP, Toppmeyer D, Moreno-Aspitia A, Rugo HS, Ratain MJ, Gobburu J. A model-based approach to dose optimization of neurotoxic chemotherapy for metastatic breast cancer (MBC). Journal of Clinical Oncology. 33: 1041-1041. DOI: 10.1200/Jco.2015.33.15_Suppl.1041 |
0.356 |
|
| 2015 |
Sagara Y, Barry WT, Mallory MA, Wong SM, Aydogan F, DeSantis S, Golshan M. The survival benefit offered by the surgical management of low-grade ductal carcinoma in situ of the breast. Journal of Clinical Oncology. 33: 1006-1006. DOI: 10.1200/Jco.2015.33.15_Suppl.1006 |
0.403 |
|
| 2015 |
Sikov WM, Barry WT, Hoadley KA, Pitcher BN, Singh B, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, Golshan M, Berry DA, Hahn OM, Carey LA, Perou CM, et al. Abstract S4-05: Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) or bevacizumab (Bev): CALGB 40603/150709 (Allianc Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-S4-05 |
0.485 |
|
| 2015 |
Hoadley KA, Barry WT, Pitcher BN, Parker JS, Wilkerson MD, Irvin W, Henry NL, Tolaney SM, Dang C, Krop IE, Berry DA, Mardis ER, Perou CM, Winer EP, Hudis CA, et al. Abstract S3-06: Mutational analysis of CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-S3-06 |
0.433 |
|
| 2015 |
Jeselsohn RM, Barry WT, Zhao J, Buchwalter G, Guarducci C, Migliaccio I, Biagioni C, Bonechi M, Laing N, Rukazenkov Y, Winer EP, Brown M, Leo AD, Malorni L. Abstract S1-01: TransCONFIRM: The correlative analysis of breast tumors from patients with advanced hormone receptor positive disease identifies a genetic signature associated with decreased benefit from single agent fulvestrant Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-S1-01 |
0.511 |
|
| 2015 |
Wagle N, Lin NU, Richardson AL, Leshchiner I, Mayer IA, Forero-Torres A, Hobday TJ, Dees EC, Nanda R, Rimawi MF, Guo H, Barry WT, Bose R, Shen W, Wolff AC, et al. Abstract PD3-5: Whole exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients with or without prior trastuzumab (T): A correlative analysis of TBCRC003 Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-Pd3-5 |
0.401 |
|
| 2015 |
Iglesia MD, Vincent BG, Serody JS, Carey LA, Barry WT, Sikov WM, Hudis CA, Winer EM, Perou CM. Abstract PD1-2: Impact of tumor-infiltrating B-cell clonal diversity on response to neoadjuvant therapy in triple negative and HER2+ breast cancer treated on CALGB (Alliance) 40601 and 40603 Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-Pd1-2 |
0.476 |
|
| 2015 |
Richardson AL, Silver DP, Szallasi Z, Birkbak NJ, Wang ZC, Iglehart JD, Mayer EL, Winer EP, Tung NM, Ryan PD, Isakoff SJ, Barry WT, Greene-Collozi A, Gutin A, Reid J, et al. Abstract P3-06-11: Homologous recombination deficiency (HRD) assay predicts response to cisplatin neoadjuvant chemotherapy in patients with triple negative breast cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P3-06-11 |
0.474 |
|
| 2015 |
Sagara Y, Barry WT, Vaz-Luis I, Aydogan F, Brock JE, Winer EP, Golshan M, Metzger-Filho O. Abstract P1-16-01: Effect of margin width on local recurrence in invasive lobular carcinoma treated with multimodality therapy Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P1-16-01 |
0.466 |
|
| 2014 |
Barry WT, Birrer MJ, Lee JM, Buckanovich RJ, Fleming GF, Rimel B, Buss MK, Nattam SR, Hurteau J, Luo W, Quy P, Obermayer E, Whalen C, Lee H, Winer EP, et al. A randomized phase 2 trial comparing efficacy of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: LBA5500. PMID 28141978 DOI: 10.1200/Jco.2014.32.18_Suppl.Lba5500 |
0.388 |
|
| 2014 |
Burstein HJ, Cirrincione CT, Barry WT, Chew HK, Tolaney SM, Lake DE, Ma C, Blackwell KL, Winer EP, Hudis CA. Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 3959-66. PMID 25348000 DOI: 10.1200/Jco.2014.56.7941 |
0.432 |
|
| 2014 |
Carey LA, Barry W. Making sense of dual HER2-targeting in early breast cancer? Journal of the National Cancer Institute. 106. PMID 25224563 DOI: 10.1093/jnci/dju259 |
0.325 |
|
| 2014 |
Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel B, Buss MK, Nattam S, Hurteau J, Luo W, Quy P, Whalen C, Obermayer L, Lee H, et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. The Lancet. Oncology. 15: 1207-14. PMID 25218906 DOI: 10.1016/S1470-2045(14)70391-2 |
0.428 |
|
| 2014 |
Prat A, Lluch A, Albanell J, Barry WT, Fan C, Chacón JI, Parker JS, Calvo L, Plazaola A, Arcusa A, Seguí-Palmer MA, Burgues O, Ribelles N, Rodriguez-Lescure A, Guerrero A, et al. Predicting response and survival in chemotherapy-treated triple-negative breast cancer. British Journal of Cancer. 111: 1532-41. PMID 25101563 DOI: 10.1038/Bjc.2014.444 |
0.454 |
|
| 2014 |
Ruddy KJ, DeSantis SD, Barry W, Guo H, Block CC, Borges V, Winer EP, Partridge AH. Extended therapy with letrozole and ovarian suppression in premenopausal patients with breast cancer after tamoxifen. Clinical Breast Cancer. 14: 413-6. PMID 24970714 DOI: 10.1016/j.clbc.2014.04.007 |
0.353 |
|
| 2014 |
Myers A, Barry WT, Hirsch MS, Matulonis U, Lee L. β-Catenin mutations in recurrent FIGO IA grade I endometrioid endometrial cancers. Gynecologic Oncology. 134: 426-7. PMID 24952365 DOI: 10.1016/J.Ygyno.2014.06.010 |
0.331 |
|
| 2014 |
Sheppard VB, Faul LA, Luta G, Clapp JD, Yung RL, Wang JH, Kimmick G, Isaacs C, Tallarico M, Barry WT, Pitcher BN, Hudis C, Winer EP, Cohen HJ, Muss HB, et al. Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 2318-27. PMID 24934786 DOI: 10.1200/Jco.2013.51.7367 |
0.426 |
|
| 2014 |
Faul LA, Luta G, Sheppard V, Isaacs C, Cohen HJ, Muss HB, Yung R, Clapp JD, Winer E, Hudis C, Tallarico M, Wang J, Barry WT, Mandelblatt JS. Associations among survivorship care plans, experiences of survivorship care, and functioning in older breast cancer survivors: CALGB/Alliance 369901. Journal of Cancer Survivorship : Research and Practice. 8: 627-37. PMID 24917307 DOI: 10.1007/S11764-014-0371-5 |
0.399 |
|
| 2014 |
Stevenson M, Christensen J, Shoemaker D, Foster T, Barry WT, Tong BC, Wahidi M, Shofer S, Datto M, Ginsburg G, Crawford J, D'Amico T, Ready N. Tumor acquisition for biomarker research in lung cancer. Cancer Investigation. 32: 291-8. PMID 24810245 DOI: 10.3109/07357907.2014.911880 |
0.34 |
|
| 2014 |
Freedman RA, Vaz-Luis I, Barry WT, Lii H, Lin NU, Winer EP, Keating NL. Patterns of chemotherapy, toxicity, and short-term outcomes for older women receiving adjuvant trastuzumab-based therapy. Breast Cancer Research and Treatment. 145: 491-501. PMID 24756187 DOI: 10.1007/S10549-014-2968-9 |
0.388 |
|
| 2014 |
Freedman RA, Luis IMVD, Barry WT, Krop IE, Wagle N, Lowe A, Galler S, Sohl J, Isakoff SJ, Tung NM, Winer EP, Lin NU. A phase II study of eribulin mesylate in combination with trastuzumab and pertuzumab in patients (pts) with metastatic, human epidermal growth factor receptor 2-positive breast cancer. Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.Tps668 |
0.457 |
|
| 2014 |
Metzger-Filho O, Barry WT, Krop IE, Younger WJ, Lawler ES, Winer EP, Lin NU. Phase I dose-escalation trial of ONT-380 in combination with trastuzumab in participants with brain metastases from HER2+ breast cancer. Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.Tps660 |
0.462 |
|
| 2014 |
Mayer EL, Gropper AB, Tung NM, Higgins MJ, Traina TA, Barry WT, Winer EP, Burstein HJ. Adjuvant palbociclib (P) plus endocrine therapy (ET) for hormone receptor positive (HR+) breast cancer: A phase II feasibility study. Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.Tps654 |
0.447 |
|
| 2014 |
Mayer EL, Vaz-Luis I, Richardson AL, Perou CM, Tung NM, Abramson VG, Anders CK, Forero-Torres A, Marcom PK, Miller K, Puhalla S, Rimawi MF, Stearns V, Traina TA, Barry WT, et al. TBCRC030: A randomized, phase II study of preoperative cisplatin versus paclitaxel in patients (pts) with BRCA1/2-proficient triple-negative breast cancer (TNBC)—Evaluating the homologous recombination deficiency (HRD) biomarker. Journal of Clinical Oncology. 32: TPS1145-TPS1145. DOI: 10.1200/Jco.2014.32.15_Suppl.Tps1145 |
0.413 |
|
| 2014 |
Truong SR, Barry WT, Moslehi JJ, Baker E, Mayer EL, Partridge AH. Evaluating the utility of baseline cardiac function assessment in early-stage breast cancer treatment. Journal of Clinical Oncology. 32: 6590-6590. DOI: 10.1200/Jco.2014.32.15_Suppl.6590 |
0.418 |
|
| 2014 |
Konstantinopoulos P, Makker V, Barry WT, Liu J, Horowitz NS, Birrer MJ, Doyle LA, Berlin ST, Whalen C, Hummelen PV, Coleman RL, Aghajanian C, Mills GB, Matulonis U, Westin SN, et al. Phase II, single stage, cohort expansion study of MK-2206 in recurrent endometrial serous cancer. Journal of Clinical Oncology. 32: 5515-5515. DOI: 10.1200/Jco.2014.32.15_Suppl.5515 |
0.388 |
|
| 2014 |
Wagle N, Lin NU, Richardson AL, Leshchiner I, Mayer IA, Forero-Torres A, Hobday TJ, Dees EC, Nanda R, Rimawi MF, Guo H, Barry WT, Wolff AC, Gabriel SB, Garraway LA, et al. Whole-exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients (pts) treated with prior trastuzumab (T): A correlative analysis of TBCRC003. Journal of Clinical Oncology. 32: 536-536. DOI: 10.1200/Jco.2014.32.15_Suppl.536 |
0.397 |
|
| 2014 |
Carey LA, Barry WT, Pitcher B, Hoadley KA, Cheang MCU, Anders CK, Henry NL, Tolaney SM, Dang CT, Krop IE, Harris L, Berry DA, Perou CM, Winer EP, Hudis CA. Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa). Journal of Clinical Oncology. 32: 506-506. DOI: 10.1200/Jco.2014.32.15_Suppl.506 |
0.489 |
|
| 2014 |
Tolaney SM, Guo H, Barry WT, Larrabee K, Brock JE, Wagle N, Allen EMV, Paweletz C, Ivanova E, Janne PA, Overmoyer B, Wright JJ, Shapiro G, Winer EP, Krop IE. A phase II study of tivantinib (ARQ-197) for metastatic triple-negative breast cancer. Journal of Clinical Oncology. 32: 1106-1106. DOI: 10.1200/Jco.2014.32.15_Suppl.1106 |
0.476 |
|
| 2013 |
Mandelblatt JS, Makgoeng SB, Luta G, Hurria A, Kimmick G, Isaacs C, Tallarico M, Barry WT, Pitcher B, Winer EP, Hudis C, Cohen HJ, Muss HB. A planned, prospective comparison of short-term quality of life outcomes among older patients with breast cancer treated with standard chemotherapy in a randomized clinical trial vs. an observational study: CALGB #49907 and #369901. Journal of Geriatric Oncology. 4: 353-61. PMID 24472479 DOI: 10.1016/J.Jgo.2013.05.004 |
0.364 |
|
| 2013 |
Liu JF, Kindelberger D, Doyle C, Lowe A, Barry WT, Matulonis UA. Predictive value of circulating tumor cells (CTCs) in newly-diagnosed and recurrent ovarian cancer patients. Gynecologic Oncology. 131: 352-6. PMID 23954902 DOI: 10.1016/J.Ygyno.2013.08.006 |
0.373 |
|
| 2013 |
Brown JQ, Bydlon TM, Kennedy SA, Caldwell ML, Gallagher JE, Junker M, Wilke LG, Barry WT, Geradts J, Ramanujam N. Optical spectral surveillance of breast tissue landscapes for detection of residual disease in breast tumor margins. Plos One. 8: e69906. PMID 23922850 DOI: 10.1371/Journal.Pone.0069906 |
0.388 |
|
| 2013 |
Jones LW, Fels DR, West M, Allen JD, Broadwater G, Barry WT, Wilke LG, Masko E, Douglas PS, Dash RC, Povsic TJ, Peppercorn J, Marcom PK, Blackwell KL, Kimmick G, et al. Modulation of circulating angiogenic factors and tumor biology by aerobic training in breast cancer patients receiving neoadjuvant chemotherapy. Cancer Prevention Research (Philadelphia, Pa.). 6: 925-37. PMID 23842792 DOI: 10.1158/1940-6207.Capr-12-0416 |
0.431 |
|
| 2013 |
Ligibel JA, Cirrincione C, Liu MC, Citron ML, Ingle JN, Gradishar WJ, Martino S, Sikov WM, Michaelson RA, Hudis C, Winer EP, Barry WT. Body mass index (BMI), tumor subtype, and relapse-free survival (RFS) in CALGB 9741 (Alliance). Journal of Clinical Oncology. 31: 1032-1032. DOI: 10.1200/Jco.2013.31.15_Suppl.1032 |
0.35 |
|
| 2013 |
Tolaney S, Barry W, Dang C, Yardley D, Moy B, Marcom P, Albain K, Rugo H, Ellis M, Shapira I, Wolff A, Carey L, Overmoyer B, Partridge A, Guo H, et al. Abstract S1-04: A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC) Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-S1-04 |
0.453 |
|
| 2013 |
Horton J, Blitzblau R, Yoo S, Georgiade G, Geradts J, Baker J, Chang Z, Broadwater G, Barry W, Duffy E, Hwang E. Abstract P5-14-04: Preoperative single-fraction partial breast radiotherapy – Initial results from a novel phase I dose-escalation protocol with exploration of radiation response biomarkers Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P5-14-04 |
0.439 |
|
| 2013 |
Frank E, Price K, Colten M, Fax R, Levine M, Matyka C, Dowton A, Barry W, Winer E, Partridge A. Abstract P4-18-01: Sharing clinical trial results with patient participants: A project of the Dana Farber/Harvard Cancer Center (DF/HCC) breast cancer research advocacy group Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P4-18-01 |
0.404 |
|
| 2013 |
Partridge A, Ruddy K, Barry W, Greaney M, Sprunck-Harrild K, Meyer M, Baker E, Ligibel J, Emmons K. Abstract OT2-4-02: Young and strong: A randomized trial to evaluate a program for young women with breast cancer Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-Ot2-4-02 |
0.407 |
|
| 2012 |
Bydlon TM, Barry WT, Kennedy SA, Brown JQ, Gallagher JE, Wilke LG, Geradts J, Ramanujam N. Advancing optical imaging for breast margin assessment: an analysis of excisional time, cautery, and patent blue dye on underlying sources of contrast. Plos One. 7: e51418. PMID 23251526 DOI: 10.1371/Journal.Pone.0051418 |
0.389 |
|
| 2012 |
Secord AA, Teoh DK, Barry WT, Yu M, Broadwater G, Havrilesky LJ, Lee PS, Berchuck A, Lancaster J, Wenham RM. A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 5489-98. PMID 22837181 DOI: 10.1158/1078-0432.Ccr-12-0507 |
0.341 |
|
| 2012 |
Mandelblatt JS, Faul LA, Luta G, Makgoeng SB, Isaacs C, Taylor K, Sheppard VB, Tallarico M, Barry WT, Cohen HJ. Patient and physician decision styles and breast cancer chemotherapy use in older women: Cancer and Leukemia Group B protocol 369901. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 2609-14. PMID 22614985 DOI: 10.1200/Jco.2011.40.2909 |
0.419 |
|
| 2012 |
Kim MK, Osada T, Barry WT, Yang XY, Freedman JA, Tsamis KA, Datto M, Clary BM, Clay T, Morse MA, Febbo PG, Lyerly HK, Hsu DS. Characterization of an oxaliplatin sensitivity predictor in a preclinical murine model of colorectal cancer. Molecular Cancer Therapeutics. 11: 1500-9. PMID 22351745 DOI: 10.1158/1535-7163.Mct-11-0937 |
0.392 |
|
| 2012 |
Acharya CR, Hsu DS, Anders CK, Anguiano A, Salter KH, Walters KS, Redman RC, Tuchman SA, Moylan CA, Mukherjee S, Barry WT, Dressman HK, Ginsburg GS, Marcom KP, Garman KS, et al. Retraction: Acharya CR, et al. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA. 2008;299(13):1574-1587. Jama. 307: 453. PMID 22228686 DOI: 10.1001/Jama.2012.2 |
0.394 |
|
| 2012 |
Ibarra-Drendall C, Troch MM, Barry WT, Broadwater G, Petricoin EF, Wulfkuhle J, Liotta LA, Lem S, Baker JC, Ford AC, Wilke LG, Zalles C, Kuderer NM, Hoffman AW, Shivraj M, et al. Pilot and feasibility study: prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathways. Breast Cancer Research and Treatment. 132: 487-98. PMID 21647677 DOI: 10.1007/S10549-011-1609-9 |
0.378 |
|
| 2012 |
Bydlon TM, Brown JQ, Kennedy SA, Gallagher JE, Caldwell M, Junker M, Wilke LG, Barry WT, Geradts J, Ramanujam N. Optical Spectral Imaging For Breast Margin Assessment: A Comprehensive Assessment of Sources of Contrast Ieee Transactions On Biomedical Engineering. DOI: 10.1364/Biomed.2012.Bw2B.4 |
0.317 |
|
| 2012 |
Rugo HS, Barry WT, Moreno-Aspitia A, Lyss AP, Cirrincione C, Mayer EL, Naughton M, Layman RM, Carey LA, Somer RA, Perez EA, Hudis C, Winer EP. CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC). Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.Cra1002 |
0.354 |
|
| 2012 |
Freedman R, Pitcher B, Keating N, Barry W, Ballman K, Kornblith A, Mandelblatt J, Kimmick G, Hurria A, Winer E, Hudis C, Cohen H, Muss H. Abstract P6-08-05: Changes in Cognitive Function in Older Women With Breast Cancer Treated with Standard Chemotherapy and Capecitabine within CALGB 49907 Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P6-08-05 |
0.347 |
|
| 2012 |
Barry W, Marcom P, Geradts J, Datto M. Abstract P4-09-01: Retrospective evaluation of precision of gene-expression-based signatures of prognosis and tumor biology in replicate surgical biospecimens from patients with breast cancer Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P4-09-01 |
0.475 |
|
| 2012 |
Lyman G, Culakova E, Poniewierski, Wogu A, Barry W, Ginsburg G, Marcom P, Ready N, Abernethy A, Geradts J, Hwang S, Kuderer N. Abstract P3-06-07: Ki67 as a Predictive Marker of Response to Neoadjuvant Chemotherapy in Patients with Early-Stage Breast Cancer (ESBC): A Systematic Review and Evidence Summary Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P3-06-07 |
0.435 |
|
| 2012 |
Kuderer N, Barry W, Geradts J, Ginsburg G, Lyman G, Datto M, Liotcheva V, Isner P, Veldman T, Agarwal P, Hwang S, Ready N, Marcom P. Abstract P2-10-03: A cross-platform comparison of genomic signatures and OncotypeDx score to discover potential prognostic/predictive genes and pathways Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P2-10-03 |
0.457 |
|
| 2012 |
Liu M, Pitcher B, Mardis E, Davies S, Snider J, Vickery T, Reed J, DeSchryver K, Singh B, Friedman P, Gradishar W, Perez E, Martino S, Citron M, Norton L, ... ... Barry W, et al. Abstract P2-10-01: PAM50 gene signature is prognostic for breast cancer patients treated with adjuvant anthracycline and taxane based chemotherapy Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P2-10-01 |
0.478 |
|
| 2012 |
Ibarra-Drendall C, Troch MM, Barry WT, Broadwater G, Petricoin EF, Wulfkuhle J, Liotta LA, Lem S, Baker JC, Ford AC, Wilke LG, Zalles C, Kuderer NM, Hoffman AW, Shivraj M, et al. Erratum: Pilot and feasibility study: Prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathways (Breast Cancer Research and Treatment (2012) 132 (487-498) DOI: 10.1007/s10549-011-1609-9) Breast Cancer Research and Treatment. 135. DOI: 10.1007/S10549-012-2227-X |
0.431 |
|
| 2011 |
Kuderer NM, Culakova E, Huang M, Poniewierski MS, Ginsburg GS, Barry WT, Marcom PK, Ready N, Abernethy AP, Lyman GH. Quality appraisal of clinical validation studies for multigene prediction assays of chemotherapy response in early-stage breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3082. PMID 28022514 DOI: 10.1200/Jco.2011.29.15_Suppl.3082 |
0.449 |
|
| 2011 |
Owzar K, Barry WT, Jung SH. Statistical considerations for analysis of microarray experiments. Clinical and Translational Science. 4: 466-77. PMID 22212230 DOI: 10.1111/J.1752-8062.2011.00309.X |
0.327 |
|
| 2011 |
Salter KH, Acharya CR, Walters KS, Redman R, Anguiano A, Garman KS, Anders CK, Mukherjee S, Dressman HK, Barry WT, Marcom KP, Olson J, Nevins JR, Potti A. Retraction: An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer. Plos One. 6. PMID 21912632 DOI: 10.1371/annotation/8f94e479-4161-43a0-a28c-4c0460bb89a4 |
0.333 |
|
| 2011 |
Freedman JA, Augustine CK, Selim AM, Holshausen KC, Wei Z, Tsamis KA, Hsu DS, Dressman HK, Barry WT, Tyler DS, Nevins JR. A methodology for utilization of predictive genomic signatures in FFPE samples. Bmc Medical Genomics. 4: 58. PMID 21745407 DOI: 10.1186/1755-8794-4-58 |
0.354 |
|
| 2011 |
Hurria A, Cirrincione CT, Muss HB, Kornblith AB, Barry W, Artz AS, Schmieder L, Ansari R, Tew WP, Weckstein D, Kirshner J, Togawa K, Hansen K, Katheria V, Stone R, et al. Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401 Journal of Clinical Oncology. 29: 1290-1296. PMID 21357782 DOI: 10.1200/Jco.2010.30.6985 |
0.354 |
|
| 2011 |
Pilie PG, Ibarra-Drendall C, Troch MM, Broadwater G, Barry WT, Petricoin EF, Wulfkuhle JD, Liotta LA, Lem S, Baker JC, Stouder A, Ford AC, Wilke LG, Zalles CM, Mehta P, et al. Protein microarray analysis of mammary epithelial cells from obese and nonobese women at high risk for breast cancer: feasibility data. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 20: 476-82. PMID 21242333 DOI: 10.1158/1055-9965.Epi-10-0847 |
0.407 |
|
| 2011 |
Teoh D, Ayeni TA, Rubatt JM, Adams DJ, Grace L, Starr MD, Barry WT, Berchuck A, Murphy SK, Secord AA. Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells. Gynecologic Oncology. 121: 187-92. PMID 21208651 DOI: 10.1016/J.Ygyno.2010.11.017 |
0.348 |
|
| 2011 |
Ibarra-Drendall C, Ford A, Tolbert N, Frye E, Lee L, Broadwater G, Barry W, Petricoin E, Liota L, Seewaldt V. Abstract CN07-03: IL6 and AKT as targets for chemoprevention Cancer Prevention Research. 4. DOI: 10.1158/1940-6207.Prev-11-Cn07-03 |
0.414 |
|
| 2011 |
Culakova E, Poniewierski, Huang M, Kuderer N, Ginsburg G, Barry W, Marcom P, Ready N, Abernethy A, Lyman G. P3-14-04: Assessment of Genomic Prognostic Signatures as Predictors of Response to Neoadjuvant Chemotherapy in Patients with Early Stage Breast Cancer. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P3-14-04 |
0.451 |
|
| 2011 |
Barry W, Chen W, Sfakianos G, Isner P, Datto M, Kuderer N, Lyman G, Abernethy A, Ginsburg G, Berchuck A. OP 54 A genomic-based signature of response to chemotherapy in ovarian cancer fails to predict clinical outcome in two independent cohorts. European Journal of Cancer. 47. DOI: 10.1016/S0959-8049(11)72620-X |
0.37 |
|
| 2010 |
Brown JQ, Bydlon TM, Richards LM, Yu B, Kennedy SA, Geradts J, Wilke LG, Junker M, Gallagher J, Barry W, Ramanujam N. Optical assessment of tumor resection margins in the breast. Ieee Journal of Selected Topics in Quantum Electronics : a Publication of the Ieee Lasers and Electro-Optics Society. 16: 530-544. PMID 21544237 DOI: 10.1109/Jstqe.2009.2033257 |
0.431 |
|
| 2010 |
Kennedy S, Geradts J, Bydlon T, Brown JQ, Gallagher J, Junker M, Barry W, Ramanujam N, Wilke L. Optical breast cancer margin assessment: an observational study of the effects of tissue heterogeneity on optical contrast. Breast Cancer Research : Bcr. 12: R91. PMID 21054873 DOI: 10.1186/Bcr2770 |
0.383 |
|
| 2010 |
Gatti DM, Barry WT, Nobel AB, Rusyn I, Wright FA. Heading down the wrong pathway: on the influence of correlation within gene sets. Bmc Genomics. 11: 574. PMID 20955544 DOI: 10.1186/1471-2164-11-574 |
0.616 |
|
| 2010 |
Geradts J, Bean SM, Bentley RC, Barry WT. The oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features. Cancer Investigation. 28: 969-77. PMID 20873988 DOI: 10.3109/07357907.2010.512600 |
0.397 |
|
| 2010 |
Wang X, Osada T, Wang Y, Yu L, Sakakura K, Katayama A, McCarthy JB, Brufsky A, Chivukula M, Khoury T, Hsu DS, Barry WT, Lyerly HK, Clay TM, Ferrone S. CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer. Journal of the National Cancer Institute. 102: 1496-512. PMID 20852124 DOI: 10.1093/Jnci/Djq343 |
0.432 |
|
| 2010 |
Mandelblatt JS, Sheppard VB, Hurria A, Kimmick G, Isaacs C, Taylor KL, Kornblith AB, Noone AM, Luta G, Tallarico M, Barry WT, Hunegs L, Zon R, Naughton M, Winer E, et al. Breast cancer adjuvant chemotherapy decisions in older women: the role of patient preference and interactions with physicians. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 3146-53. PMID 20516438 DOI: 10.1200/Jco.2009.24.3295 |
0.434 |
|
| 2010 |
Barry WT, Kernagis DN, Dressman HK, Griffis RJ, Hunter JD, Olson JA, Marks JR, Ginsburg GS, Marcom PK, Nevins JR, Geradts J, Datto MB. Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcome. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 2198-206. PMID 20368555 DOI: 10.1200/Jco.2009.26.7245 |
0.451 |
|
| 2010 |
Gatza ML, Lucas JE, Barry WT, Kim JW, Wang Q, Crawford MD, Datto MB, Kelley M, Mathey-Prevot B, Potti A, Nevins JR. A pathway-based classification of human breast cancer. Proceedings of the National Academy of Sciences of the United States of America. 107: 6994-9. PMID 20335537 DOI: 10.1073/Pnas.0912708107 |
0.414 |
|
| 2010 |
Hartman ZC, Wei J, Osada T, Glass O, Lei G, Yang XY, Peplinski S, Kim DW, Xia W, Spector N, Marks J, Barry W, Hobeika A, Devi G, Amalfitano A, et al. An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicity. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 1466-77. PMID 20179231 DOI: 10.1158/1078-0432.Ccr-09-2549 |
0.351 |
|
| 2010 |
Morse MA, Wei J, Hartman Z, Xia W, Ren XR, Lei G, Barry WT, Osada T, Hobeika AC, Peplinski S, Jiang H, Devi GR, Chen W, Spector N, Amalfitano A, et al. Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo. International Journal of Cancer. 126: 2893-903. PMID 19856307 DOI: 10.1002/Ijc.24995 |
0.402 |
|
| 2010 |
Marcom PK, Barry W, Datto MB, Geradts J, Olson JA, Marks J, Lyman GH, Potti A, Ginsburg GS, Nevins JR. A randomized phase II trial evaluating the performance of genomic expression profiles to direct the use of preoperative chemotherapy for early-stage breast cancer. Journal of Clinical Oncology. 28: TPS102-TPS102. DOI: 10.1200/Jco.2010.28.15_Suppl.Tps102 |
0.497 |
|
| 2010 |
Potti A, Vlahovic G, Dunphy F, Barry W, Datto MB, D'Amico TA, Crawford J, Ginsburg GS, Nevins JR, Ready N. Implementing genomically-guided trials in non-small cell lung carcinoma (NSCLC). Journal of Clinical Oncology. 28: e18003-e18003. DOI: 10.1200/Jco.2010.28.15_Suppl.E18003 |
0.34 |
|
| 2010 |
Geradts J, Bean SM, Bentley RC, Barry W. Correlation of the Oncotype DX recurrence score with a composite index comprised of ER, PR, HER2, and breast tumor grade. Journal of Clinical Oncology. 28: 10647-10647. DOI: 10.1200/Jco.2010.28.15_Suppl.10647 |
0.437 |
|
| 2010 |
Barry W, Acharya C, Datto MB, Dressman HK, Marcom PK, Ready N, Ginsburg GS, Potti A, Nevins JR. Utilization of genomic signatures for chemotherapy response in prospective clinical studies. Journal of Clinical Oncology. 28: 10513-10513. DOI: 10.1200/Jco.2010.28.15_Suppl.10513 |
0.351 |
|
| 2010 |
Seewaldt VL, Ibarra-Drendall C, Pilie P, Barry W, Broadwater G, Petricoin E. Abstract A108: Phosphoprotein network activation during breast cancer initiation Cancer Prevention Research. 3. DOI: 10.1158/1940-6207.Prev-10-A108 |
0.435 |
|
| 2010 |
Pilie PG, Ibarra C, Troch M, Dietze E, Broadwater G, Barry W, Petricoin C, Seewaldt VL. Abstract A15: Proteomic profiling of early mammary carcinogenesis: Targeting dysregulated protein pathways with tailored therapies Clinical Cancer Research. 16. DOI: 10.1158/1078-0432.Tcmusa10-A15 |
0.453 |
|
| 2010 |
Burstein H, Barry W, Cirrincione C, Chew H, Tolaney S, Lake D, Pluard T, Blackwell K, Winer E, Hudis C. Abstract PD05-01: CALGB 40302: Fulvestrant with or without Lapatinib as Therapy for Hormone Receptor Positive Advanced Breast Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Study Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-Pd05-01 |
0.499 |
|
| 2010 |
Brown JQ, Bydlon TM, Kennedy SA, Geradts J, Wilke LG, Barry W, Richards LM, Junker MK, Gallagher J, Ramanujam N. Assessment of breast tumor margins via quantitative diffuse reflectance imaging Progress in Biomedical Optics and Imaging - Proceedings of Spie. 7573. DOI: 10.1117/12.841949 |
0.345 |
|
| 2009 |
Mandelblatt J, Sheppard V, Hurria A, Kimmick G, Isaacs C, Taylor K, Luta G, Noone A, Kornblith A, Barry W. Patient preference as a determinant of breast cancer adjuvant chemotherapy use in older women: CALGB #369901. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 9544. PMID 27963610 DOI: 10.1200/Jco.2009.27.15_Suppl.9544 |
0.447 |
|
| 2009 |
Marcom PK, Datto MB, Barry WT, Geradts J, Foster TL, Dressman HK, Olson J, Potti A, Ginsburg G, Nevins JR. Implementation of genomic predictors of chemotherapy response for guiding preoperative therapy in a prospective breast cancer trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 11057. PMID 27963164 DOI: 10.1200/Jco.2009.27.15_Suppl.11057 |
0.475 |
|
| 2009 |
Stevenson M, Mostertz W, Acharya C, Kim W, Walters K, Barry W, Higgins K, Tuchman SA, Crawford J, Vlahovic G, Ready N, Onaitis M, Potti A. Characterizing the Clinical Relevance of an Embryonic Stem Cell Phenotype in Lung Adenocarcinoma Clinical Cancer Research. 15: 7553-7561. PMID 19996213 DOI: 10.1158/1078-0432.Ccr-09-1939 |
0.362 |
|
| 2009 |
Friedman DR, Weinberg JB, Barry WT, Goodman BK, Volkheimer AD, Bond KM, Chen Y, Jiang N, Moore JO, Gockerman JP, Diehl LF, Decastro CM, Potti A, Nevins JR. A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 6947-55. PMID 19861443 DOI: 10.1158/1078-0432.Ccr-09-1132 |
0.301 |
|
| 2009 |
Wilke LG, Brown JQ, Bydlon TM, Kennedy SA, Richards LM, Junker MK, Gallagher J, Barry WT, Geradts J, Ramanujam N. Rapid noninvasive optical imaging of tissue composition in breast tumor margins. American Journal of Surgery. 198: 566-74. PMID 19800470 DOI: 10.1016/J.Amjsurg.2009.06.018 |
0.353 |
|
| 2009 |
Mendiratta P, Mostaghel E, Guinney J, Tewari AK, Porrello A, Barry WT, Nelson PS, Febbo PG. Genomic strategy for targeting therapy in castration-resistant prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2022-9. PMID 19289629 DOI: 10.1200/Jco.2008.17.2882 |
0.313 |
|
| 2009 |
Hsu DS, Acharya CR, Balakumaran BS, Riedel RF, Kim MK, Stevenson M, Tuchman S, Mukherjee S, Barry W, Dressman HK, Nevins JR, Powers S, Mu D, Potti A. Characterizing the developmental pathways TTF-1, NKX2-8, and PAX9 in lung cancer. Proceedings of the National Academy of Sciences of the United States of America. 106: 5312-7. PMID 19279207 DOI: 10.1073/Pnas.0900827106 |
0.376 |
|
| 2009 |
Vasilatos SN, Broadwater G, Barry WT, Baker JC, Lem S, Dietze EC, Bean GR, Bryson AD, Pilie PG, Goldenberg V, Skaar D, Paisie C, Torres-Hernandez A, Grant TL, Wilke LG, et al. CpG island tumor suppressor promoter methylation in non-BRCA-associated early mammary carcinogenesis. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 18: 901-14. PMID 19258476 DOI: 10.1158/1055-9965.Epi-08-0875 |
0.442 |
|
| 2009 |
Tuchman S, Acharya C, Mostertz W, Barry W, Gasparetto C, Barlogie B, Potti A, Shaughnessy JD. Gene Expression Profiling Reveals 5-Azacytidine to Be a Novel, Potentially Effective Therapy for Poor-Prognosis Patients with Multiple Myeloma. Blood. 114: 1833-1833. DOI: 10.1182/Blood.V114.22.1833.1833 |
0.363 |
|
| 2008 |
Garst J, Datto M, Herndon JE, Barry WT, Shoemaker D, Bjurstrom A, Andrews C, Ginsburg G, Nevins JR, Potti A. A phase II prospective study evaluating the role of pemetrexed plus gemcitabine (Pem/Gem) chemotherapy as intial treatment in patients with stage IIIB/IV non-small cell lung cancer (NSCLC) using a genomic predictor of cisplatin-resistance to guide therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 8108. PMID 27948813 DOI: 10.1200/Jco.2008.26.15_Suppl.8108 |
0.369 |
|
| 2008 |
Mendiratta P, Tewari A, Guinney J, Porrello A, Barry WT, Febbo PG. A genomic strategy for targeting therapy in castration-Independent Prostate Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5067. PMID 27948753 DOI: 10.1200/Jco.2008.26.15_Suppl.5067 |
0.304 |
|
| 2008 |
Barry WT, Datto M, Geradts J, Foster T, Olson J, Marcom PK, Dressman HK, Nevins JR, Ginsburg G, Potti A. Genomic-based signatures of chemosensitivity and ER/HER2 status in biologic replicate breast cancer samples. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 11068. PMID 27947719 DOI: 10.1200/Jco.2008.26.15_Suppl.11068 |
0.484 |
|
| 2008 |
Garman KS, Acharya CR, Edelman E, Grade M, Gaedcke J, Sud S, Barry W, Diehl AM, Provenzale D, Ginsburg GS, Ghadimi BM, Ried T, Nevins JR, Mukherjee S, Hsu D, et al. A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. Proceedings of the National Academy of Sciences of the United States of America. 105: 19432-7. PMID 19050079 DOI: 10.1073/Pnas.0806674105 |
0.435 |
|
| 2008 |
Owzar K, Barry WT, Jung SH, Sohn I, George SL. Statistical challenges in preprocessing in microarray experiments in cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 5959-66. PMID 18829474 DOI: 10.1158/1078-0432.Ccr-07-4532 |
0.357 |
|
| 2008 |
Acharya CR, Hsu DS, Anders CK, Anguiano A, Salter KH, Walters KS, Redman RC, Tuchman SA, Moylan CA, Mukherjee S, Barry WT, Dressman HK, Ginsburg GS, Marcom KP, Garman KS, et al. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. Jama. 299: 1574-87. PMID 18387932 DOI: 10.1001/Jama.299.13.1574 |
0.447 |
|
| 2008 |
Salter KH, Acharya CR, Walters KS, Redman R, Anguiano A, Garman KS, Anders CK, Mukherjee S, Dressman HK, Barry WT, Marcom KP, Olson J, Nevins JR, Potti A. An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer. Plos One. 3: e1908. PMID 18382681 DOI: 10.1371/Journal.Pone.0001908 |
0.426 |
|
| 2008 |
Barry WT, Nobel AB, Wright FA. A statistical framework for testing functional categories in microarray data Annals of Applied Statistics. 2: 286-315. DOI: 10.1214/07-Aoas146 |
0.615 |
|
| 2005 |
Barry WT, Nobel AB, Wright FA. Significance analysis of functional categories in gene expression studies: a structured permutation approach. Bioinformatics (Oxford, England). 21: 1943-9. PMID 15647293 DOI: 10.1093/Bioinformatics/Bti260 |
0.617 |
|
| 2003 |
Hester SD, Benavides GB, Yoon L, Morgan KT, Zou F, Barry W, Wolf DC. Formaldehyde-induced gene expression in F344 rat nasal respiratory epithelium. Toxicology. 187: 13-24. PMID 12679049 DOI: 10.1016/S0300-483X(03)00008-8 |
0.303 |
|
| Show low-probability matches. |